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Abstract: Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence
has increased over the last few decades. It derives from follicular thyroid cells. Generally speaking,
the prognosis is excellent. If treatment according to the current guidelines is given, cases of recurrence
or persistence are rare. DTC requires special expertise by the treating physician. In recent years,
new therapeutic options for these patients have become available. For this article we performed
a systematic literature review with special focus on the guidelines of the American Thyroid
Association, the European Association of Nuclear Medicine, and the German Society of Nuclear
Medicine. For DTC, surgery and radioiodine therapy followed by levothyroxine substitution remain
the established therapeutic procedures. Even metastasized tumors can be cured this way. However,
in rare cases of radioiodine-refractory tumors, additional options are to be discussed. These include
strict suppression of thyroid-stimulating hormone (also known as thyrotropin, TSH) and external local
radiotherapy. Systemic cytostatic chemotherapy does not play a significant role. Recently, multikinase
or tyrosine kinase inhibitors have been approved for the treatment of radioiodine-refractory DTC.
Although a benefit for overall survival has not been shown yet, these new drugs can slow down
tumor progression. However, they are frequently associated with severe side effects and should be
reserved for patients with threatening symptoms only.
Keywords: differentiated thyroid cancer; radioiodine therapy; targeted therapy; tyrosine kinase
inhibitors
1. Introduction
Patients with differentiated thyroid carcinoma have an excellent prognosis. The multimodal
therapeutic approach is risk-adapted to achieve optimal treatment of differentiated thyroid cancer
(DTC) and to minimize treatment-related morbidity. The treatment includes surgery (near-/total
thyroidectomy) usually followed by remnant ablation using radioiodine according to the guidelines of
the American Thyroid Association (ATA) and European Association of Nuclear Medicine (EANM) as
well as a risk-stratified follow-up including hormone substitution.
However, in patients with primary or secondary radioiodine-refractory thyroid carcinoma the
prognosis becomes significantly poorer. External beam irradiation may be used for locoregional control.
Receptor tyrosine kinase inhibitors (TKIs) have shown clinical effectiveness in iodine-refractory DTC.
In this review, we present the current state of treatment of DTC.
2. Epidemiology and Classification
DTC is a rare disease with mostly excellent prognosis. The appearance of DTC depends on age,
sex, family history, radiation exposure and many other factors [1]. DTC occurs in 7–15% of patients
with thyroid surgery. In the year 2014, approximately 63,000 new cases of DTC were diagnosed in the
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US [2] compared to 2009 with only 31,200 new cases. In Germany there are about 6000 new cases of
DTC per year. The growing incidence of thyroid cancer and the tumor shift to diagnosis of smaller
tumors is due to the increased usage of diagnostic methods, such as ultrasound of the neck [3].
Differentiated thyroid cancer includes papillary and follicular cancer that derive from thyrocytes
and express the sodium iodine symporter. DTC represents the majority (90%) of all types of thyroid
cancer [4]. One study predicts that papillary thyroid cancer will become the third most expensive
cancer in women, with costs of US$ 19–21 billion in the US in 2019 [5].
Worldwide, there are many clinical practice guidelines for diagnosis, therapy and follow-up of
DTC. The European Thyroid Association (ETA) published new guidelines for the management of DTC
in 2013 [6]. The Society for Nuclear Medicine and Molecular Imaging and European Association of
Nuclear Medicine published their most recent guidelines for radioiodine therapy of differentiated
thyroid cancer in 2012 and 2008, respectively [7,8]. The Japanese Association of Endocrine Surgeons
and the Japanese Society of Thyroid Surgeons recently reviewed their guidelines in 2014 [9]. The new
ATA guidelines for management of differentiated thyroid cancer for adults were published in 2015 [10].
The updated ATA guidelines for management of DTC for children were also published in 2015 [11].
The risk classification of DTC using multiple staging systems is based on a combination of the size
of the primary tumor, specific histology, extrathyroidal spread of the tumor and the age at diagnosis.
It helps to predict the risk of local recurrence and developing metastases and the mortality in patients
with DTC. The TNM classification depends on the size of primary tumor, the number and localization
of metastatic lymph nodes and number of distant metastases (Table 1) [12]. The American Joint
Committee on Cancer (AJCC) uses the combination of TNM Classification and an age of more than
55 years at diagnosis as risk factor [13]. The differentiation of lymphatic invasion and angioinvasion
is of high importance, because angioinvasion is associated with an intermediate risk of recurrence.
A common risk-stratification of DTC is based on the TNM classification (see also Section 4.2) [14]:
• high-risk group: pT3, pT4, each N1, all M1;
• low-risk group: pT1b, pT2, cN0/pN0, cM0;
• very low risk-group: pT1a, cN0/pN0, cM0.
Table 1. TNM Classification of thyroid cancer, 8th edition (modified from [12]).
TX Primary Tumor Cannot be Assessed
T0 No evidence of primary tumor
T1 Tumor size maximum 2 cm, limited to the thyroid
T1a Tumor size maximum 1 cm, limited to the thyroid
T1b Tumor size >1 cm up to a maximum of 2 cm, limited to the thyroid
T2 Tumor size >2 cm up to 4 cm, limited to the thyroid
T3 Tumor size >4 cm, limited to the thyroid, or any tumor with macroscopic extrathyroidal extension(Musculus sternohyoideus, Musculus sternothyreoideus, Musculus omohyoideus)
T3a Tumor size >4 cm, limited to the thyroid
T3b Any tumor with macroscopic extrathyroidal extension (M. sternohyoideus, M. sternothyreoideus, M. omohyoideus)
T4a Any tumor size with extrathyroidal extension beyond the thyroid capsule and invasion of subcutaneous soft tissue, larynx,trachea, esophagus and/or recurrent laryngeal nerve
T4b Any tumor size with invasion of prevertebral fascia, mediastinal vessels or carotid artery
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
N1a Lymph node metastases unilateral in level VI or upper mediastinum
N1b Metastases in other unilateral, bilateral or contralateral cervical lymph nodes (level I, II, III, IV and V) or retropharyngeal
M0 No distant metastases
M1 Distant metastases
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The American Thyroid Association defines in their current guideline a stratification based on the
risk of structural disease recurrence [10]:
• high-risk group: gross extrathyreoidal extension, incomplete tumor resection, distant metastases,
or lymph node >3 cm;
• intermediate-risk: aggressive histology, minor extrathyreoidal extension, vascular invasion,
or >5 involved lymph nodes (0.2–3 cm);
• low-risk: intrathyreoidal DTC, ≤5 lymph nodes micrometastases (<0.2 cm).
In the last few years new molecular and genetic biomarkers, such as BRAF (V600E),
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA), tumor protein p53
(TP53), RAC-α serine/threonine-protein kinase 1 (AKT1) and telomerase reverse transcriptase (TERT)
became more important for the management of diagnosis, therapy and observing of DTC. The role
of RAS is discussed controversally. Table 2 shows the impact of the two well-evaluated molecular
markers BRAF and TERT [15]. Some of these alterations might be interesting molecular targets for
new therapies.
Table 2. Mutations of BRAF and TERTp in follicular-derived thyroid carcinoma and clinicopathological
impact (modified from [15]).
Mutation Histology Clinicopathological Associations
BRAF papillary thyroid carcinoma (PTC)
recurrence, multifocality, extrathyreoidal
extension, lymph nodes metastasis, advanced
stage, absence of capsule, vascular invasion,
more aggressive histological subtype
BRAF micro PTC multifocality, extrathyreoidal extension,advanced stage, lymph node metastasis
BRAF thyroid carcinoma derived fromfollicular cells no association
TERT papillary thyroid carcinoma
more advanced stage by tall cell variant, higher
tumor size, vascular invasion, older age, poor
outcome, lymph node and distant metastasis
TERT thyroid carcinoma derived fromfollicular cells
more aggressive histologic variants, concomitant
presence of mutated RAS/BRAF, age > 45, higher
tumor size, vascular invasion, persistent or
recurrent disease, lymph node metastasis
2.1. Papillary Thyroid Cancer
Papillary thyroid carcinoma (PTC) is the most common form of DTC. Histologically it is a tumor of
follicular cells of the thyroid gland with characteristic nuclear signs. There are more than 10 histological
variants of papillary thyroid cancer documented, can be seen in Table 3 [16,17]. Due to this microscopic
diversity, different risk stratifications are needed.
The tall cell variant is one of the tumor entities with unfavorable outcome. This type of thyroid
cancer is presented in tall columnar cells and occurs in older age showing a higher rate of lymph node
metastases. In nearly 80% of these tumors the BRAF (V600E) mutation is found [18]. A new aggressive
variant of papillary thyroid carcinoma, which is characterized by cells with hobnail appearance and
apically placed nuclei, was described recently. The BRAF (V600E) mutation is found frequently and
associated with distant metastases [19]. In children and adults affected by the Chernobyl incident the
solid variant of PTC appears predominantly. Mortality within the first 10 years after initial diagnosis
and treatment is low (<1%) [20,21]. It is very important to recognize that there are histological
differences compared to poorly differentiated carcinomas, because of the very different therapy
strategy. In poorly differentiated thyroid cancer the capability to take up (radio) iodine is clearly
reduced (e.g., decreased expression of sodium iodine symporter) and therefore not sufficient to
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achieve a significant therapeutic effect. Another form of PTC is the diffuse sclerosing variant. It is
characterized by a higher incidence of lymph node and distant metastases. Nevertheless, overall
mortality appears low. The encapsulated follicular variant of papillary carcinoma very rarely shows
capsular or vascular invasion. Histologically it is characterized by follicular growth, typical nuclear
features of papillary carcinoma and total tumor encapsulation. RAS mutations can be detected
frequently. The non-encapsulated follicular variant of papillary cancer shows BRAF (V600E) mutations
quite often [22,23]. This tumor is associated with lymph node metastases in about 25–30% and low
rates of distant metastases.
Table 3. WHO classification of papillary and follicular carcinoma of the thyroid (modified from [17]).
Histology Histological Variants
Papillary carcinoma
Classic (usual)
Clear cell variant
Columnar cell variant
Cribriform-morular variant
Diffuse sclerosing variant
Follicular variant
Macrofollicular variant
Microcarcinoma (occult, latent, small, microtumor)
Oncocytic or oxyphilic variant (follicular/nonfollicular variant)
Solid variant
Tall cell variant
Warthin-like variant
Follicular carcinoma
Clear cell variant
Oncocytic (Hürthle cell) variant
Mucinous variant
With signet-ring cells
PTC presents distant metastases mainly in bones or lungs.
Papillary microcarcinoma is a PTC < 1 cm corresponding to the classification of the World
Health Organization (WHO) which is often found incidentally. In some autopsy studies the papillary
microcarcinoma was found in 6–35% of the thyroids by incident [10]. Papillary microcarcinoma may
also exhibit RET proto-oncogene (RET)/PTC-rearrangements or BRAF (V600E) mutations.
2.2. Follicular Thyroid Cancer
Follicular thyroid carcinoma (FTC) is a malignant tumor, histologically derived from follicular
thyroid cells, showing transcapsular or vascular invasion and missing the typical nuclear signs of
papillary carcinoma. In the traditional classification of FTC there are two groups: minimally invasive
and widely invasive [24–26]. The widely invasive FTC shows an extensive vascular invasion, often
also associated with extrathyroidal growth.
Oncocytic follicular carcinoma is a special form of FTC with some microscopic differences
compared to conventional FTC. One of them is the accumulation of innumerable mitochondria. Due to
its histological differences, oncocytic carcinoma shows some different biological behavior with a higher
ability to metastasize to lymph nodes and a possibly higher rate of recurrence and tumor-related
mortality [27–29].
2.3. Familial Tumor Syndromes
Some of the histopathological variants of DTC are associated with familial tumor syndromes.
For example, the cribriform-morular form of papillary thyroid cancer is frequently seen in patients
with a germline mutation in adenomatous polyposis coli gene [30,31]. About 40% of patients with this
special histological form of papillary thyroid carcinoma show simultaneously a familial adenomatous
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polyposis (FAP) [32]. Due to this high rate of association of cribriform-morular PTC and FAP it is very
important to complete the diagnostic work-up with colonoscopy and genetic counseling.
Another type of FTC is associated with the germline mutation of the phosphatase and tensin
homolog (PTEN) gene [33–35]. The follicular variant of thyroid carcinoma is in this case very
characteristic and should be known by pathologists. The syndrome is associated with a high risk of
appearance of other tumors, such as colon hamartomas or breast and endometrium tumors. Genetic
counseling is recommended.
3. Diagnostic Approach to Thyroid Nodules
The prevalence of sonographically-detected thyroid nodules in the U.S. is described between 19%
and 35% [36]. Toxic adenomas are found in up to 4 percent of the population. In Europe the incidence
of thyroid nodules is higher in some areas. In Germany, a country with relative iodine deficiency,
nodules are found in 33% of the population.
Risk factors for malignancy are exposure to ionizing radiation through radiotherapy or fallout
especially in younger years, familial thyroid carcinoma, or syndromes that are associated with thyroid
cancer like PTEN, Cowdens disease or multiple endocrine neoplasia type 2 (MEN2). Warning signs in
clinical examination are rapid nodule growth, fixation in the surrounding tissue, vocal cord paralysis,
possibly accompanied by hoarseness.
The diagnostic cornerstone of thyroid nodules remains the ultrasound examination. It should be
performed in any case of known or suspected thyroid nodules or cervical lymphadenopathy to assess
if further diagnostic is needed. Sonographic patterns suspicious of malignancy are microcalcifications,
irregular margins, solid consistency, hypoechogenity, extrathyroidal extension (ETE) and a tall shape
rather than a wide one. Intranodulary vascularization does not seem to have a clear correlation with
malignancy [10].
Roughly one third of thyroid nodules are larger than 1 cm and eligible for scintigraphy [37].
The guidelines of the German Society of Nuclear Medicine recommend a scintigraphic examination of
every thyroid nodule >1 cm. By routinely performing a Tc-99m thyroid scan autonomous adenomas
that have not yet an impact on thyroid-stimulating hormone (TSH) level can be detected without
subjecting the patient to the risks and stress of fine-needle aspiration (FNA). This applies especially to
groups at increased risk for complications like patients that are treated with coagulation inhibitors.
The diagnostic algorithm for evaluation of thyroid nodules according to the German guidelines that
was recently published by Feldkamp et al. is shown in Figure 1 [38].
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The ATA guidelines recommend measurement of the TSH level if a thyroid nodule is found.
A radionuclide scan (Tc-99m, preferable I-123) should be performed only if TSH level is subnormal [10].
Nevertheless, the American guidelines cannot be applied to the rest of the world without adjustment for
differences in the patient populations. Except for clearly benign cysts, for every lesion of a certain size
ultrasound guided fine-needle aspiration biopsy (FNA) is recommended (Table 4) [10]. Furthermore,
the measurement of serum calcitonin is recommended when new thyroid nodules are detected time to
rule out medullary thyroid cancer that derives from c-cells and is not added to group of DTC.
Table 4. Sonographic patterns and risk of malignancy (modified from [10]).
Ultrasound Features Estimated Risk ofMalignancy
Sonographic
Pattern FNA Size Cutoff
Solid hypoechogenic nodule or solid hypoechogenic
component of a partially cystic nodule with one or
more of the following features: irregular margins,
microcalcification, taller rather than wide shape, rim
calcifications with small extrusive soft tissue
component, evidence of extrathyroidal extension (ETE)
>70–90% Highlysuspicious >1 cm
Solid hypoechogenic nodule with smooth margins
without microcalcification, taller rather than wide
shape or signs of ETE
10–20% Intermediatesuspicion >1 cm
Isoechogenic solid nodule or partally cystic nodule
with eccentric solid areas without microcalcification,
taller rather than wide shape or signs of ETE
5–10% Low suspicion >1.5 cm
Spongiform or partially cystic nodule without any of
the sonographic features described above <3%
Very low
suspicion
>2 cm, alternative:
observation without fine
needle aspiration (FNA)
Purely cystic nodules without solid components <1% Benign No biopsy
Cytological analysis is performed according to the Bethesda System for Reporting Thyroid
Cytopathology. The findings are graded into six categories:
I: nondiagnostic/unsatisfactory;
II: benign;
III: atypia of undetermined significance/follicular lesion of undetermined significance;
IV: follicular neoplasm/suspicious for follicular neoplasm;
V: suspicious for malignancy;
VI: malignant.
If the FNA biopsy is graded non-diagnostic/unsatisfactory, biopsy should be repeated. Numerous
molecular tests can be applied to distinguish malignant from benign lesions, such as BRAF (V600E),
PIK3CA and TERT promoter, AKT1, and TP53, although there is no explicit recommendation in
the current guidelines. Accordingly, adjustments are to be expected in the future [15]. For more
non-diagnostic biopsies in a row, the decision for close surveillance without intervention or for surgery
should be made in dependence of the sonographic pattern [10].
4. Therapy of Differentiated Thyroid Carcinoma
DTC should be treated interdisciplinary in facilities with an appropriate expertise in order to
ensure an optimal long-term treatment quality. Specialists in surgery, endocrinology, pathology and
nuclear medicine should be available. The therapeutic approach is individualized and risk-adapted.
4.1. Surgery
For widely invasive follicular thyroid carcinomas and FTC with vascular infiltration,
thyreoidectomy is recommended. Lymph node dissection is recommended if lymph node metastases
can be detected pre- or intraoperatively by sonographic examination and/or palpation. The solitary
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minimally invasive FTC without vascular invasion does not require a second surgical intervention
as completion, if the tumor has been completely removed (R0). Thyreoidectomy and lymph node
dissection of the central compartment are recommended for prognostically unfavorable variants.
For all papillary thyroid carcinomas >1 cm and/or for all metastasized or macroscopically invasive
PTC irrespective of size, thyreoidectomy is recommended [10,39]. If lymph node metastases have
been detected sonographically or intraoperatively, lymph node dissection in the affected compartment
should be done to reduce the risk of (local) recurrence. On the other hand, the diagnostic or therapeutic
extirpation of only single lymph nodes as a part of the primary intervention is not recommended.
Although at present the importance of central lymph dissection with prophylactic intention is still
unclear, the high probability of lymph node metastases is a substantial argument to expand the surgical
procedure. Furthermore, it is difficult to exclude lymph node metastases pre- or intraoperatively.
After all, the increased risk of a local recurrence associated with an increased morbidity due to the
surgical intervention in the situation of relapse should be mentioned. On the other hand, the main
arguments against a prophylactic dissection are the lack of evidence regarding a better outcome of
the patients and the remarkably higher complication rate due to the more extensive intervention
(e.g., vocal cord paralysis, parathyreoprival tetany). Specifically, papillary thyroid microcarcinoma
that is found incidentally does not require a further surgical treatment.
After all, accurate histopathological examination of the specimen after (hemi)thyroidectomy and
lymphadenectomy (if done) is regarded as the gold standard and is indispensable for the management
and further diagnostic and therapeutic approach.
4.2. Adjuvant Radioiodine Therapy
Radioiodine therapy (RIT) has been established for more than 60 years. The benefit was
demonstrated in DTC patients with a high risk for recurrence. In patients with very low-risk DTC
a positive effect of a RIT on tumor-free and overall survival has not been proven by prospective
clinical trials.
RIT is defined as the systemic administration of I-131 (radioiodine as sodium iodide or potassium
iodide) to irradiate thyroid remnants as well as non-resectable or incompletely resected DTC.
Adjuvant ablative RIT of thyroid remnants or tumor tissue is the optimal precondition for
the follow-up including determination of serum thyroglobulin (Tg) and I-131 whole-body scans.
The rationale that underlies this approach is to detect a local recurrence or distant metastases in
an early and potentially curable stage to minimize mortality. However, regional or distant metastases
frequently are only detectable by rising Tg levels after a successful remnant-ablation. It was shown
that an ablative RIT decreases the rate of recurrence and mortality over a follow-up period of more
than 10 years [40–43]. RIT is indicated in high-risk DTC (pT3, pT4, each N1, every M1), in low-risk
DTC (pT1b, pT2, cN0, pN0, M0) and in small papillary thyroid carcinoma (very low-risk DTC),
if there are risk factors (see Section 4.7) [44,45]. Furthermore, RIT can be used for the treatment of
radioiodine-positive tumor residues, lymph node and distant metastases with curative or palliative
intention. In the case of tumor activity shown by an increasing serum level of thyroglobulin without
a macroscopically detectable tumor using morphological and functional imaging RIT can be carried
out after carefully weighing risks and benefits [14].
To ensure a high uptake of radioiodine (I-131) in remnant tissue, (suspected) tumor, or metastases,
an elevated serum level of TSH is required (>30 mU/L). This level is believed to increase the
expression of the sodium iodine symporter (NIS) in benign and malignant follicular cells of the
thyroid [46]. According to the guidelines of the ATA and EANM [8,10] this TSH level can be reached by
waiting not less than 3 weeks after thyroidectomy or after a withdrawal (4–5 weeks) of levothyroxine
(LT4). The subsequent period of hypothyroidism decreases the quality of life significantly in many
patients. The physical and psychological symptoms of hypothyroidism include gain of weight,
impaired renal function, cardiovascular abnormalities, dyslipidemia (exacerbation), constipation,
dry skin, hoarseness, fatigue, sleep disturbance, impaired ability to concentrate and depression [47].
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Alternatively, recombinant TSH (rhTSH) can be administered intramuscularly (2 times 0.9 mg rhTSH)
to avoid inconvenience and morbidity due to the lack of thyroid hormone. This drug is approved for
radioiodine ablation (without known distant metastases) of T1–4 tumors, diagnostic whole-body scan
and preparation for testing of serum Tg in adults [48–51].
Absolute contraindications of RIT are pregnancy and breastfeeding. Relative contraindications
include depression of the bone marrow (especially if the administration of high activities of I-131 is
planned), a restriction of salivary gland function, pulmonary function restriction (if a high accumulation
of I-131 in lung metastases is possible) and symptomatic metastases of the central nervous system,
because local edema and inflammation caused by RIT and hypothyroidism can lead to severe
compression effects [8].
The activity of I-131 for remnant ablation is still discussed controversially. The HiLo study
(Great Britain) and the ESTIMABL study (France) both compared ablative RIT with 1.1 GBq I-131
versus administration of 3.7 GBq (100 mCi) I-131 after thyroid hormone withdrawal or stimulation
with rhTSH in patients with low-risk carcinoma [52,53]. Both studies showed that RIT with only 1.1
GBq (30 mCi) I-131 is not inferior compared to the higher activity in regard to the success of ablation.
However, the definition of “success of ablation” used in both studies is not accepted by all departments
and associations. Several authors report that the rate of a second RIT increases when low therapy
activities were used initially [54,55].
In the ESTIMABL study the diagnostic I-131-whole-body scan 8 months after I-131 ablation was
limited to patients with elevated Tg antibodies and disturbed Tg recovery. Even in this subgroup
this concept was not consistently implemented. Based on an observation study, iodine-accumulating
metastases are possible with a measurable Tg level of up to 1 ng/mL [56]. Due to the open question
of the “optimal” activity for remnant ablation, the German Society of Nuclear Medicine for example
recommends a single administration of 1 to 3.7 GBq (about 30–100 mCi) I-131 [14]. Preablation scanning
with Tc-99m pertechnetate on the day of ablation (as used in the HiLo trial [52]) can give very useful
information in clinical decision making. In low-risk DTC patients with a large remnant (multiple foci
or one large focus) ablation with 3.7 GBq (30 mCi) may be prefered.
Although RIT is generally well tolerated, the procedure has some potential short- and long-term
side effects [8]. Short-term risks/side effects are: thyroiditis due to irradiation, swelling of the tumor
or metastases (including compression symptoms), gastritis and nausea, sialadenitis and abnormalities
of taste and smell, bone marrow depression, and hypospermia.
Long-term risks and side effects include permanent bone marrow depression, second primary
malignancy after RIT with a high cumulative activity (leukemia and solid tumors) [57], chronic
sialadenitis (including abnormalities of taste and smell, xerostomia,) and pulmonary fibrosis
(in patients with diffuse iodine-avid pulmonary metastases). Due to the risk of chronic hypospermia
or azoospermia, sperm banking should be considered if high cumulative activities are expected [58].
These risks have to be weighed against the expected benefits of the RIT.
4.3. Metastatic Differentiated Thyroid Carcinoma
Distant metastases occur in patients with differentiated thyroid carcinoma with a prevalence of
up to 10%. In particular, they affect lung and bone [59]. If a sufficient uptake of I-131 in metastases is
measurable, different therapeutic approaches are to be weighed regarding risk and benefit.
If locoregional lymph node metastases are detectable, surgery should be performed. I-131 is
used for iodine-avid metastases for treatment control after surgery or as an alternative therapy if no
surgery is possible/planned (e.g., additional detection of distant metastases requiring RIT, previously
performed radiotherapy, previous lymph node dissection).
In the case of micronodulary metastases of the lung RIT is carried out as a treatment with
curative intent. Macronodulary pulmonary metastases should also be treated with I-131 in a curative
intention but a complete remission is unlikely. Alternatively, (or in combination) the resectability can
be evaluated.
Int. J. Mol. Sci. 2017, 18, 1292 9 of 17
The complete surgical resection of isolated bone metastases leads to an improved outcome.
A combination of different therapeutic approaches like percutaneous radiotherapy, RIT and local
interventional therapy could be helpful if symptomatic metastases of the bone cannot be (completely)
resected. The same strategy is applied to brain metastases [14].
For the treatment of metastases, standard activities of 4–11 GBq (about 100–300 mCi) I-131 are
given depending on individual patient characteristics like age, renal function, bone marrow depression
and tumor load.
4.4. Thyroid Hormone Treatment
After thyroidectomy, life-long thyroid hormone therapy is required, usually as monotherapy with
levothyroxine (LT4). Since TSH is able to promote the growth of remaining DTC cells, the dosage of LT4
should initially be high enough to achieve a suppression of thyrotropin. The thyroid function should
be checked after 6 to 8 weeks. Depending on the result the dosage should be adjusted. An elevated
level of triiodothyronine has to be avoided.
A long-term suppression of TSH to values <0.1 mU/L is currently only recommended for
high-risk patients and patients with persistent disease indefinitely in the absence of specific
contraindications [10]. In these cases, a better prognosis was demonstrated for the suppression
of thyrotropin. No evidence-based data are available for optimal duration of TSH suppression.
According to the guidelines of the ATA, serum TSH should be maintained between 0.1 and
0.5 mU/L in patients with high-risk disease but excellent or intermediate response to therapy for up
to 5 years and also in patients with a biochemical incomplete response taking into account the initial
ATA risk classification published by Haugen et al. [10]. This recommendation is rated as weak with
low-quality evidence. If the response to therapy is excellent biochemically and clinically in patients
with a low risk for recurrence and there is no evidence of disease in the course of time, the serum level
of TSH may be kept in a range of 0.5–2.0 mU/L, because there is no data showing a benefit of TSH
suppression for low-risk patients.
Individual patient-related factors such as osteoporosis or osteopenia and cardiac co-morbidities
like atrial fibrillation should always be taken into account during thyroid hormone therapy and
weighed against the risk of recurrence. Especially in elderly patients >60 years, the use of TSH
suppressive therapy should be carefully considered since the risk of such complications is significantly
increased [60].
4.5. Follow-Up
Although the cumulative relapse rate is up to 30%, the life expectancy of DTC patients
(pT1-3, pN0-1, M0) is not significantly different from the general population after therapy according
to the current guidelines. Lifelong follow-up examinations should be carried out because relapses
can occur even after decades and may be cured again. Initial checks should be carried out every
six months (e.g., for the first 5 years after diagnosis). If there are no pathological findings later on,
annual examinations are adequate [61]. The follow-up examination is based on the medical interview,
clinical examination, cervical sonography, determination of TSH, triiodothyronine, levothyroxine,
and thyroglobulin including Tg antibodies. In the case of postoperative hypoparathyroidism, the
substitution therapy (cholecalciferol, calcium) should be checked and adapted (if necessary) to
minimize the risk of osteoporosis.
A diagnostic whole-body scan is obligatory 6–12 months after initial RIT, a second scan is only
needed in the case of relapse [10,62].
The criteria for a disease-free stage 6–12 months after primary therapy of DTC with total
thyroidectomy ± radioiodine therapy are no clinical signs of DTC, no pathological uptake in
the I-131 whole-body scan (only after remnant ablation) and a serum Tg below the detection
limit (under suppression and after TSH stimulation, with absence of Tg antibodies) [10,62,63].
Under these conditions patients have a very low probability of relapse. If there are signs of
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relapse (e.g., elevated/rising serum levels of Tg) and no radioiodine-accumulating tumor tissue
is detectable, clinical diagnostics should include the search for non-radioiodine-avid tumor tissue
using F-18-fluorodeoxy-glucose positron emission tomography (FDG-PET) combined with computed
tomography ideally under TSH-stimulation.
4.6. Tyrosine Kinase Inhibitors
For poorly differentiated thyroid carcinoma without relevant iodine metabolism and therefore
very low radioiodine uptake, RIT is not a therapeutic option. Radioiodine resistance is currently
defined as lesions without iodine uptake under TSH stimulation, progression in size in the year
following RIT or persistent metastases after a cumulative dose of 22 GBq (600 mCi) I-131 of radioiodine.
In these cases, complimentary diagnostic using FDG-PET/computed tomography (CT) is essential.
FDG uptake is typically increased in poorly differentiated lesions that can be overlooked on radioiodine
scans. Prognosis for radioiodine resistant thyroid cancer with distant metastases is very poor, with
an estimated median survival time of about 2.5 to 3.5 years [64,65].
Chemotherapy comes at high toxicity with disappointing response rates [66]. For these patients
a strict LT4 regime with TSH suppression is the best way to go. On showing rapid progression under
such a regime, therapy options were few until recently.
Tyrosine kinase inhibitors like vandetanib, sorafenib and lenvatinib are a relatively new approach to
systemic therapy in these cases. Tyrosine kinase receptors, the target structure of TKI, are trans-membrane
proteins that mediate cell survival and proliferation [67]. If mutated, they can cause uncontrolled cell
proliferation, dedifferentiation and apoptosis reduction. A large part of DTC show at least one mutation
of RAF, RET or paired box gene 8 (PAX8)/peroxisome proliferator-activated receptor gamma (PPARγ)
which makes them targets for TKI therapy. Furthermore, TKIs block receptors of the vascular endothelial
growth factor (VEGF), fibroblast growth factor receptors and platelet-derived growth factor and thus
inhibit tumor angiogenesis and lymphangiogenesis and cause hypoxia in malignant tissue [68]. TKIs,
already approved for the treatment of irresectable liver cancer and renal carcinoma, promise to be
an effective new tool for the treatment of poorly differentiated thyroid carcinoma (PDTC) [66].
A recent review on the use of sorafenib, sunitinib and lenvatinib showed a benefit for
progression-free survival of up to five months [69]. While initially showing partial response or at
least disease stabilization after sorafenib, the first TKI approved for thyroid cancer, patients almost
always develop resistance over the course of the following one to two years. Switching to another TKI
is possible at this point [70]. A study using lenvatinib was able to indicate prolonged progression-free
survival regardless of BRAF or RAS mutation status, suggesting a diminished role of these pathways [71].
However, a benefit in overall survival could not be found.
Therapy with kinase inhibitors may be accompanied by severe side effects. Induced hypertension
is one of the most common; the underlying pathophysiology is yet unclear. Vasoconstriction following
reduced nitric oxide production via inhibition of the VEGF-PI3K pathway is discussed. A reduction
of peripheral arterioles due to antiangiogenic effects resulting in increased peripheral resistance and
an activation of the endothelin-1-system causing vasoconstriction have also been suggested [72].
Other side effects may include diarrhea, fatigue, hepatotoxicity, skin changes, nausea, increased LT4
dosage requirement, changes in taste and weight loss and associated with a severe decrease of quality
of life [69].
Keeping this in mind kinase inhibitors can certainly not be considered as a standard regime or
an alternative to TSH-suppression. For patients with radioiodine-refractory DTC they can be a useful
complementation to standard therapy.
While undergoing TKI therapy patients can display somewhat inconclusive lab results. Normally
a reliable parameter, thyroglobulin levels can fluctuate under TKI treatment. These changes do
not necessarily represent the actual course of the disease as it is monitored in anatomical imaging.
Sufficient therapeutic monitoring not only by relying on lab tests but also on CT or PET/CT diagnosis
to determine a morphologic or metabolic response is essential [73].
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Considering the extensive side effects, this therapy should be reserved for patients with rapid
tumor progression and severe to life threatening symptoms. In these cases, the decision for TKI
therapy should be made in a interdisciplinary manner, carefully weighed against local strategies like
radiotherapy and local surgery [74]. TKI treatment should only be performed by a team of physicians
experienced with side effects management.
The European guidelines for treating differentiated thyroid carcinoma are from 2008. Kinase
inhibitors are therefore not considered there [8] and a unanimous European recommendation is
still awaited.
4.7. Papillary Microcarcinoma
Because of the excellent prognosis of papillary microcarcinoma (PTMC), a hemithyroidectomy
without RIT is regarded as sufficient therapy, if there is no sign of local invasion, lymph node and/or
distant metastases. The substitution of LT4 should keep the serum level of TSH in a euthyroid
metabolic state.
In a meta-analysis, PTMC showed a prevalence of distant metastases of 0.4%, a probability of
locoregional relapse of 2.5% but also a prevalence of micrometastases in locoregional lymph nodes of
12–50% [45]. The risk of lymphogenic micrometastases increases with increasing tumor diameter [75].
Using single photon emission computed tomography (SPECT) combined with CT, other studies
showed a prevalence of lymph node metastases up to 57% [76,77]. The relapse-free survival in patients
with PTMC after 5 years was 78.6% without RIT compared to 95.0% in patients that have had a remnant
ablation with RIT [78]. The recommendation for a RIT in PTMC is based on the extent of resection and
the individual risk profile. Risk factors are multifocality, infiltration of the thyroid gland, histological
variants of papillary thyroid carcinoma, low degree of differentiation, tumor diameter 6–10 mm,
molecular markers like BRAF-V600E mutation, infiltrative tumor growth, surrounding desmoplastic
fibrosis and previous percutaneous irradiation of the neck [14]. In patients with a residual thyroid
gland (e.g., after lobectomy) an ablative RIT is not indicated.
5. Summary and Conclusion
Differentiated thyroid cancer is a rare tumor entity but shows a strongly increasing incidence over
the last decades. It derives from the follicular epithelium of the thyroid and shows basic biological
characteristics of healthy thyroid tissue. The expression of the sodium iodide symporter is the key
feature for specific iodine uptake. Patients with DTC have an excellent prognosis.
The therapeutic approach including surgery and remnant ablation with radioiodine should
be risk-adapted to achieve an optimal treatment and to minimize treatment-related morbidity.
Overtreatment should be avoided.
With regard to so-called low-risk carcinoma defined by the ATA there are controversial therapeutic
approaches. The guidelines of the ATA recommend a lobectomy under certain conditions. Following
the guidelines of the EANM a thyreodectomy with RIT should be performed (except PTC pT1a).
However, long-term studies are currently not available. These studies are certainly necessary
(against the background of the slow growth of the well-differentiated thyroid carcinoma) to decide
which approach is appropriate. A risk-stratified follow-up is required since recurrences can occur over
years. Furthermore, thyroid hormone substitution must be controlled.
The life span of most DTC patients does not differ from general population when appropriate
treatment is given. The prognosis becomes poorer in patients with radioiodine refractory thyroid
carcinoma. TKI have shown clinical effectiveness in iodine-refractory DTC with regard to progression
free survival. A positive effect on overall survival could not be shown yet and has to be evaluated in
further studies. However, therapy should be carried out in centers with special expertise.
In the current guidelines of the ATA and EANM there is no evidence-based treatment concept
(or strong recommendation) for every situation. There are still open questions:
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• The value of RIT under the condition of increasing serum level of Tg without a detectable
correlatation in the morphological or functional imaging (i.e. iodine-negative whole-body scan);
• The benefit of a remnant ablation in patients with papillary microcarcinoma (very low risk of
relapse, lymph node metastasis possible);
• Optimal activities of I-131 for safe and effective radioiodine ablation;
• The role of rhTSH as preparation for RIT to treat incomplete or non-resectable local recurrence
or metastases;
• The role of a short LT4 withdrawal to reduce blood levels of iodine before RIT or diagnostic
whole-body scan.
An analysis by the Cancer Genome Atlas Research Network identifies previously unknown genetic
alterations and molecular subtypes of PTC. These alterations may lead to a more accurate diagnosis of
tumors and potentially more targeted treatment [79]. Although in the current guidelines no explicit
recommendation concerning the determination of molecular markers in the cyto-/histopathological
specimen is made, further adjustments are to be expected in the future.
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AKT1 RAC-α serine/threonine-protein kinase 1
ATA American Thyroid Association
CT computed tomography
DTC differentiated thyroid carcinoma
EANM European Association of Nuclear Medicine
ETE extrathyroidal extension
ETA European Thyroid Association
FAP familial adenomatous polyposis
FNA fine-needle aspiration biopsy
FTC follicular thyroid carcinoma
FDG-PET F-18-fluorodeoxy-glucose positron emission tomography
LT4 levothyroxine
MEN2 multiple endocrine neoplasia type 2
PAX8 paired box gene 8
PDTC poorly differentiated thyroid carcinoma
PIK3CA phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit α
PPARγ peroxisome proliferator-activated receptor gamma
PTC papillary thyroid carcinoma
PTEN phosphatase and tensin homolog
PTMC papillary microcarcinoma
RET RET proto-oncogene
rhTSH recombinant thyrotropin
RIT radioiodine therapy
SPECT single photon emission computed tomography
TERT telomerase reverse transcriptase
Tg serum thyroglobulin
TKI receptor tyrosine kinase inhibitors
TP53 tumor protein p53
TSH thyroid-stimulating hormone (also known as thyrotropin)
VEGF vascular endothelial growth factor
WHO World Health Organization
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